RhumbLine Advisers’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-32,999
| Closed | -$144K | – | 4143 |
|
|
2025
Q1 | $144K | Buy |
32,999
+1,332
| +4% | +$6K | ﹤0.01% | 3272 |
|
|
2024
Q4 | $148K | Sell |
31,667
-662
| -2% | -$4.46K | ﹤0.01% | 3341 |
|
|
2024
Q3 | $227K | Buy |
32,329
+1,508
| +5% | +$10.9K | ﹤0.01% | 3174 |
|
|
2024
Q2 | $211K | Buy |
30,821
+30,528
| +10,419% | +$284K | ﹤0.01% | 3198 |
|
|
2024
Q1 | $4.14K | Sell |
293
-1
| -0.3% | -$15 | ﹤0.01% | 4004 |
|
|
2023
Q4 | $2.21K | Hold |
294
| – | – | ﹤0.01% | 4085 |
|
|
2023
Q3 | $4.41K | Hold |
294
| – | – | ﹤0.01% | 4006 |
|
|
2023
Q2 | $4.67K | Buy |
+294
| New | +$3.09K | ﹤0.01% | 4103 |
|
|
2022
Q2 | – | Sell |
-11,921
| Closed | -$156K | – | 3089 |
|
|
2022
Q1 | $156K | Sell |
11,921
-967
| -8% | -$14.1K | ﹤0.01% | 2809 |
|
|
2021
Q4 | $227K | Sell |
12,888
-28
| -0.2% | -$561 | ﹤0.01% | 2799 |
|
|
2021
Q3 | $280K | Buy |
12,916
+211
| +2% | +$5.38K | ﹤0.01% | 2794 |
|
|
2021
Q2 | $445K | Buy |
12,705
+1,760
| +16% | +$94.8K | ﹤0.01% | 2610 |
|
|
2021
Q1 | $1.08M | Sell |
10,945
-879
| -7% | -$106K | ﹤0.01% | 2157 |
|
|
2020
Q4 | $1.28M | Buy |
11,824
+859
| +8% | +$106K | ﹤0.01% | 2036 |
|
|
2020
Q3 | $1.13M | Sell |
10,965
-872
| -7% | -$131K | ﹤0.01% | 1943 |
|
|
2020
Q2 | $2.47M | Buy |
11,837
+3,449
| +41% | +$611K | ﹤0.01% | 1608 |
|
|
2020
Q1 | $820K | Buy |
8,388
+1,066
| +15% | +$124K | ﹤0.01% | 1970 |
|
|
2019
Q4 | $843K | Buy |
7,322
+68
| +0.9% | +$5.99K | ﹤0.01% | 2159 |
|
|
2019
Q3 | $395K | Sell |
7,254
-13
| -0.2% | -$1.47K | ﹤0.01% | 2429 |
|
|
2019
Q2 | $864K | Sell |
7,267
-436
| -6% | -$36.1K | ﹤0.01% | 2118 |
|
|
2019
Q1 | $404K | Sell |
7,703
-87
| -1% | -$3.52K | ﹤0.01% | 2415 |
|
|
2018
Q4 | $245K | Buy |
7,790
+2,308
| +42% | +$93.9K | ﹤0.01% | 2635 |
|
|
2018
Q3 | $332K | Sell |
5,482
-25
| -0.5% | -$1.4K | ﹤0.01% | 2468 |
|
|
2018
Q2 | $292K | Buy |
+5,507
| New | +$331K | ﹤0.01% | 2546 |
|
|
2017
Q2 | – | Sell |
-2,870
| Closed | -$78K | – | 2922 |
|
|
2017
Q1 | $78K | Buy |
2,870
+887
| +45% | +$25.2K | ﹤0.01% | 2795 |
|
|
2016
Q4 | $58K | Sell |
1,983
-494
| -20% | -$16.1K | ﹤0.01% | 2821 |
|
|
2016
Q3 | $102K | Buy |
2,477
+50
| +2% | +$1.9K | ﹤0.01% | 2805 |
|
|
2016
Q2 | $77K | Buy |
2,427
+573
| +31% | +$25.9K | ﹤0.01% | 2942 |
|
|
2016
Q1 | $96K | Buy |
1,854
+10
| +0.5% | +$558 | ﹤0.01% | 2901 |
|
|
2015
Q4 | $176K | Buy |
1,844
+88
| +5% | +$7.73K | ﹤0.01% | 2837 |
|
|
2015
Q3 | $145K | Buy |
1,756
+68
| +4% | +$8.69K | ﹤0.01% | 2877 |
|
|
2015
Q2 | $274K | Buy |
1,688
+1,008
| +148% | +$340K | ﹤0.01% | 2718 |
|
|
2015
Q1 | $275K | Buy |
680
+268
| +65% | +$113K | ﹤0.01% | 2661 |
|
|
2014
Q4 | $222K | Buy |
+412
| New | +$159K | ﹤0.01% | 2748 |
|
Other funds holding ADVM
BCM
PWA
TCM
FLSM
5VM
VVM
RhumbLine Advisers's ADVM Position: Q2 2025 in Review
RhumbLine Advisers sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 32,999 shares — an estimated $144K sold.
RhumbLine Advisers first reported a position in ADVM in Q4 2014 and held it in 34 quarters. The position peaked at $2.47M in Q2 2020. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.
- RhumbLine Advisers reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
- RhumbLine Advisers sold 32,999 Adverum Biotechnologies shares in Q2 2025, an estimated $144K.
- RhumbLine Advisers first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 34 quarters.
- RhumbLine Advisers's Adverum Biotechnologies position peaked at $2.47M in Q2 2020.
- 58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.
Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.